48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
9 citations
,
September 2019 in “Clinical Cosmetic and Investigational Dermatology” In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.
66 citations
,
July 2003 in “International Journal of Dermatology” This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.
December 2024 in “PubMed” This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.
3 citations
,
August 2019 in “PubMed” This study found that topical corticosteroid foams are effective and generally preferred by patients for a variety of corticosteroid-responsive skin conditions, demonstrating significant clinical benefits such as improved psoriasis symptoms and hair regrowth in alopecia areata compared to traditional forms.
7 citations
,
June 2000 in “Journal of the American Academy of Dermatology” This study found that betamethasone valerate in a foam vehicle has comparable total coverage to traditional topical corticosteroid vehicles, despite less coverage per unit of foam.
104 citations
,
August 2008 in “Clinics in Dermatology” This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.
May 2015 in “Journal of The American Academy of Dermatology” 5% minoxidil foam helps women with thinning hair.
5 citations
,
January 2014 in “Asian Journal of Chemistry” This study developed a simple and cost-effective chromatographic method for simultaneously analyzing betamethasone dipropionate and calcipotriol, achieving rapid separation within 7 minutes suitable for routine applications.
15 citations
,
May 2017 in “Journal of Dermatological Treatment” In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.
3 citations
,
September 2022 in “Archives of dermatological research” In this study, fractional CO2 laser treatment for alopecia areata was found to significantly increase terminal hair and patient satisfaction compared to betamethasone valerate cream alone, highlighting its efficacy and safety both as a standalone and combined treatment.
1 citations
,
April 2009 in “Expert Review of Dermatology” This study found that the once-daily gel combining calcipotriene and betamethasone dipropionate was more effective and faster in treating scalp psoriasis compared to individual treatments, with a similar safety profile.
May 2015 in “Journal of The American Academy of Dermatology” Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
20 citations
,
January 2000 in “Dermatologic Clinics” This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.
74 citations
,
April 2005 in “Dermatologic Clinics” This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.
12 citations
,
January 2008 in “Drugs” This review critically assesses current topical therapies for scalp psoriasis and reports no new clinical results; the authors highlight the need for controlled trials to evaluate treatment efficacy.
2 citations
,
January 2021 in “Indian Journal of Dermatology, Venereology and Leprology” This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.
1 citations
,
February 2015 in “Journal of evolution of medical and dental sciences” This study concluded that 0.05% betamethasone dipropionate cream is more effective than other topical treatments for improving alopecia areata over 12 weeks.
August 2025 in “Indian Dermatology Online Journal” In this study, both methotrexate gel and betamethasone lotion were found to be effective and safe treatments for localized alopecia areata, with similar overall response rates. However, methotrexate gel had a higher incidence of local side effects, such as irritant dermatitis and itching.
36 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.
10 citations
,
January 2016 in “Global Dermatology” This study observed that zinc deficiency in humans and mice was associated with diminished allergic contact dermatitis but increased severity and duration of irritant contact dermatitis.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.
May 2015 in “Journal of The American Academy of Dermatology” Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.
September 2011 in “Journal der Deutschen Dermatologischen Gesellschaft” Effective treatments for scalp psoriasis include glucocorticosteroids, Vitamin D3 analogs, and combination therapies like calcipotriol and betamethasone dipropionate.
8 citations
,
June 2008 in “Aktuelle Dermatologie” Early diagnosis and personalized treatment are crucial for managing different types of alopecia effectively.
4 citations
,
February 2015 in “PubMed” This study found that a minoxidil foamable emu oil emulsion significantly promoted hair growth in animals compared to a marketed 5% minoxidil solution, showing increased hair follicles in the anagenic phase.
December 2019 in “International Journal of Research in Dermatology” In this randomized study, 72% of patients treated with 0.05% betamethasone dipropionate showed significant improvement in limited patchy alopecia areata compared to 36% of those using 0.05% tretinoin, suggesting BMD is more effective but further research on tretinoin is needed.
145 citations
,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.
1 citations
,
January 2015 in “Side effects of drugs annual” The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.